In 2021, the Food and Drug Administration (FDA) approved the possibility of treating EC patients with Dostarlimab, which works by inhibiting the binding of PD-1 to ligands, through the interaction of Dostarlimab with PD-L1 and PD-L2, allowing T lymphocytes to activate and attack cancer cells [27,28,29,30,31]. This evidence concerns the gene PDCD1LG2 and cancer.